CB5064 analog / CohBar - LARVOL DELTA

CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model (GlobeNewswire) - "CohBar, Inc...to treat chronic diseases and extend healthy lifespan, today announced new preclinical data confirming the efficacy of its apelin agonist peptides in a preclinical model of acute respiratory distress syndrome (ARDS)....'ARDS is a major unmet medical need and there are no approved therapeutics for this devastating condition,' stated Professor Toby Maher...'The data for CohBar's apelin agonists in this preclinical model are encouraging and support further advancement of the program towards candidate selection for clinical testing.'"

Media quote • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

CohBar to target COVID-19 associated acute respiratory distress syndrome (ARDS) with its apelin receptor agonist peptides (GlobeNewswire, CohBar, Inc.) - "'Preventing ARDS in COVID-19 patients, including the damaging effects of fluid accumulation in the lungs, hypoxemia, and cytokine storm, is critical to reducing mortality,' stated Professor Toby Maher."

Media quote • Acute Lung Injury • Acute Respiratory Distress Syndrome • Diabetes • Genetic Disorders • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Obesity • Pulmonary Disease • Respiratory Diseases • Type 2 Diabetes Mellitus